胸腺肽α1联合恩替卡韦治疗肝硬化肝功能代偿期的临床疗效及安全性观察

Clinical efficacy and safety of thymosin α1 combined with Entecavir in treatment of decompensated liver cirrhosis

目的:探讨胸腺肽α1联合恩替卡韦治疗肝硬化肝功能代偿期的临床疗效及安全性。方法:选取130例肝硬化肝功能代偿期患者作为研究对象。按照随机数字表法分为研究组与对照组,每组65例。对照组给予恩替卡韦治疗,研究组在对照组基础上联合胸腺肽α1治疗,两组均持续治疗6个月,观察并比较两组治疗效果。结果:研究组治疗总有效率为92.3%(60/65),明显高于对照组的76.9%(50/65)(P<0.05);研究组HBV-DNA、HBeAg转阴率分别为78.4%和70.8%,均明显高于对照组的43.1%和36.9%(P<0.05);治疗后,两组ALT、AST、TBIL指标均明显低于治疗前,A/G明显高于治疗前,且研究组ALT、AST、TBIL指标明显低于对照组,A/G明显高于对照组,差异均有统计学意义(P<0.05);研究组不良反应总发生率为4.6%(3/65),明显低于对照组的16.9%(11/65)(P<0.05)。结论:胸腺肽α1联合恩替卡韦治疗肝硬化肝功能代偿期的疗效确切,可改善患者肝功能,提高转阴率,且不良反应少,安全性高,具有较高的临床应用价值。

Objective： To investigate clinical efficacy and safety of thymosin α1 combined with Entecavir in treatment of decompensated liver cirrhosis. Methods： 130 patients with decompensated liver cirrhosis were selected as observation objects. According to random number table method,they were divided into study group and control group,with 65 cases in each. The control group received Entecavir treatment for 6 months,while the study group received thymosin α1 combined with Entecavir for 6 months. The treatment effects of the two groups were observed and compared. Results： The total effective rate of the study group was 92. 3%,which was significantly higher than that of the control group（ 76. 9%）（ P〈0. 05）. The HBV-DNA and HBeAg negative rates in the study group were 78. 4% and 70. 8%,respectively,which were significantly higher than the 43. 1% and 36. 9% in the control group（ P〈0. 05）.The ALT,AST,and TBIL were significantly lower in the two groups after the treatment than before the treatment,and the A/G was significantly higher than that before the treatment. The ALT,AST,and TBIL in the study group were significantly lower than those in the control group,the A/G was significantly higher than that in the control group,and the differences were statistically significant（ P〈0. 05）. The overall incidence of adverse reactions in the study group was 4. 6%,which was significantly lower than that in the control group of 16. 9%（ P〈0. 05）. Conclusions： The efficacy of thymosin α1 combined with Entecavir in the treatment of decompensated liver cirrhosis is definite. It can improve the liver function of the patients,improve the negative rate of conversion,and has fewer adverse reactions and high safety. Therefore,it has high clinical application value.